Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/annrheumdis-2020-219174 http://scihub22266oqcxt.onion/10.1136/annrheumdis-2020-219174 33293273!8491433!33293273     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33293273&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Ann+Rheum+Dis 2021 ; 80 (5): 550-557 Nephropedia Template TP {{tp|p=33293273|t=2021. Anti-inflammatory therapy for COVID-19 infection: the case for colchicine |pdf=|usr=}}{{33293273}} gab.com Text Anti-inflammatory therapy for COVID-19 infection: the case for colchicine JO: Ann Rheum Dis http://www.kidney.de/pget.php?&tw=1&pmid=33293273 #FOAvip The search for effective COVID-19 management strategies continues to evolve. Current understanding of SARS-CoV-2 mechanisms suggests a central role for exaggerated activation of the innate immune system as an important contributor to COVID-19 adverse outcomes. The actions of colchicine, one of the oldest anti-inflammatory therapeutics, target multiple mechanisms associated with COVID-19 excessive inflammation. While many COVID-19 trials have sought to manipulate SARS-CoV-2 or dampen the inflammatory response once patients are hospitalised, few examine therapeutics to prevent the need for hospitalisation. Colchicine is easily administered, generally well tolerated and inexpensive, and holds particular promise to reduce the risk of hospitalisation and mortality due to COVID-19 in the outpatient setting. Successful outpatient treatment of COVID-19 could greatly reduce morbidity, mortality and the demand for rare or expensive care resources (front-line healthcare workers, hospital beds, ventilators, biological therapies), to the benefit of both resource-replete and resource-poor regions. Twit Text FOAVip Anti-inflammatory therapy for COVID-19 infection: the case for colchicine ????Ann Rheum Dis http://www.kidney.de/pget.php?&tw=1&pmid=33293273 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33293273 #FOAvip English Wikipedia <ref>{{Cite pmid|33293273}}</ref> Anti-inflammatory therapy for COVID-19 infection: the case for colchicine #MMPMID33293273 Reyes AZ; Hu KA; Teperman J; Wampler Muskardin TL; Tardif JC; Shah B; Pillinger MH Ann Rheum Dis 2021[May]; 80 (5): 550-557 PMID33293273show ga The search for effective COVID-19 management strategies continues to evolve. Current understanding of SARS-CoV-2 mechanisms suggests a central role for exaggerated activation of the innate immune system as an important contributor to COVID-19 adverse outcomes. The actions of colchicine, one of the oldest anti-inflammatory therapeutics, target multiple mechanisms associated with COVID-19 excessive inflammation. While many COVID-19 trials have sought to manipulate SARS-CoV-2 or dampen the inflammatory response once patients are hospitalised, few examine therapeutics to prevent the need for hospitalisation. Colchicine is easily administered, generally well tolerated and inexpensive, and holds particular promise to reduce the risk of hospitalisation and mortality due to COVID-19 in the outpatient setting. Successful outpatient treatment of COVID-19 could greatly reduce morbidity, mortality and the demand for rare or expensive care resources (front-line healthcare workers, hospital beds, ventilators, biological therapies), to the benefit of both resource-replete and resource-poor regions. |*COVID-19 Drug Treatment[MESH] |Anti-Inflammatory Agents/*therapeutic use[MESH] |Colchicine/*therapeutic use[MESH] |Humans[MESH]Anti-inflammatory therapy for COVID-19 infection: the case for colchic(epmc).pdf DeepDyve Pubget Overpricing